|
1.Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int.2008;73(9):994-1007.
2.Sanchez-Gonzalez PD, Lopez-Hernandez FJ, Lopez-Novoa JM, Morales AI. An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity. Crit Rev Toxicol. 2011;41(10):803-821.
3.Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer.2007;7(8):573-584.
4.Rosenberg B, Vancamp L, Krigas T. Inhibition of Cell Division in Escherichia Coli by Electrolysis Products from a Platinum Electrode. Nature.1965;205:698-699.
5.Rosenberg B, VanCamp L, Trosko JE, Mansour VH. Platinum compounds: a new class of potent antitumour agents. Nature.1969;222(5191):385-386.
6.Harrap KR. Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat Rev.1985;12 Suppl A:21-33.
7.Knox RJ, Friedlos F, Lydall DA, Roberts JJ. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res.1986;46(4 Pt 2):1972-1979.
8.Aabo K, Adams M, Adnitt P, et al. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists'' Group. Br J Cancer.1998;78(11):1479-1487.
9.Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev.2007;33(1):9-23.
10.Zorbas H, Keppler BK. Cisplatin damage: are DNA repair proteins saviors or traitors to the cell? Chembiochem.2005;6(7):1157-1166.
11.Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005;4(4):307-320.
12.Chu E. Physicians'' Cancer Chemotherapy Drug Manual. 2011.
13.Lokich J, Anderson N. Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann Oncol.1998;9(1):13-21.
14.Barabas K, Milner R, Lurie D, Adin C. Cisplatin: a review of toxicities and therapeutic applications. Vet Comp Oncol.2008;6(1):1-18.
15.Launay-Vacher V, Rey JB, Isnard-Bagnis C, Deray G, Daouphars M. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol 2008;61(6):903-909.
16.Kuriakose GC, Kurup MG. Evaluation of renoprotective effect of Aphanizomenon flos-aquae on cisplatin-induced renal dysfunction in rats. Ren Fail. 2008;30(7):717-725.
17.Kang DG, Lee AS, Mun YJ, et al. Butein ameliorates renal concentrating ability in cisplatin-induced acute renal failure in rats. Biol Pharm Bull.2004;27(3):366-370.
18.Kawai Y, Satoh T, Hibi D, et al. The effect of antioxidant on development of fibrosis by cisplatin in rats. J Pharmacol Sci.2009;111(4):433-439.
19.Raff U, Scherzinger AL, Vargas PF, Simon JH. Quantitation of grey matter, white matter, and cerebrospinal fluid from spin-echo magnetic resonance images using an artificial neural network technique. Med Phys.1994;21(12):1933-1942.
20.Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol.2003;23(5):460-464.
21.Kawai Y, Taniuchi S, Okahara S, Nakamura M, Gemba M. Relationship between cisplatin or nedaplatin-induced nephrotoxicity and renal accumulation. Biol Pharm Bull.2005;28(8):1385-1388.
22.Karie S, Launay-Vacher V, Deray G, Isnard-Bagnis C. [Drugs renal toxicity]. Nephrol Ther. 2010;6(1):58-74.
23.Badary OA, Abdel-Maksoud S, Ahmed WA, Owieda GH. Naringenin attenuates cisplatin nephrotoxicity in rats. Life Sci.2005;76(18):2125-2135.
24.Ali BH, Al-Moundhri M, Tageldin M, et al. Ontogenic aspects of cisplatin-induced nephrotoxicity in rats. Food Chem Toxicol.2008;46(11):3355-3359.
25.Antunes LM, Darin JD, Bianchi Nde L. Effects of the antioxidants curcumin or selenium on cisplatin-induced nephrotoxicity and lipid peroxidation in rats. Pharmacol Res.2001;43(2):145-150.
26.Bearcroft CP, Domizio P, Mourad FH, Andre EA, Farthing MJ. Cisplatin impairs fluid and electrolyte absorption in rat small intestine: a role for 5-hydroxytryptamine. Gut.1999;44(2):174-179.
27.Kishore BK, Krane CM, Di Iulio D, Menon AG, Cacini W. Expression of renal aquaporins 1, 2, and 3 in a rat model of cisplatin-induced polyuria. Kidney Int.2000;58(2):701-711.
28.Townsend DM, Deng M, Zhang L, Lapus MG, Hanigan MH. Metabolism of Cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol.2003;14(1):1-10.
29.Uehara T, Watanabe H, Itoh F, et al. Nephrotoxicity of a novel antineoplastic platinum complex, nedaplatin: a comparative study with cisplatin in rats. Arch Toxicol.2005;79(8):451-460.
30.Cornelison TL, Reed E. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol.1993;50(2):147-158.
31.Arany I, Megyesi JK, Kaneto H, Price PM, Safirstein RL. Cisplatin-induced cell death is EGFR/src/ERK signaling dependent in mouse proximal tubule cells. Am J Physiol Renal Physiol.2004;287(3):F543-549.
32.Ramesh G, Reeves WB. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 2002;110(6):835-842.
33.Ramesh G, Reeves WB. TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure. Am J Physiol Renal Physiol.2003;285(4):F610-618.
34.Vickers AE, Rose K, Fisher R, Saulnier M, Sahota P, Bentley P. Kidney slices of human and rat to characterize cisplatin-induced injury on cellular pathways and morphology. Toxicol Pathol.2004;32(5):577-590.
35.Hamilton RW, Hopkins MB, 3rd, Shihabi ZK. Myoglobinuria, hemoglobinuria, and acute renal failure. Clin Chem.1989;35(8):1713-1720.
36.Klaasen. Casarett & Doull’s Toxicology: The Basic Science of Poisons, 6th edn. Mc Graw-Hill, New York. 2001.
37.Kroning R, Lichtenstein AK, Nagami GT. Sulfur-containing amino acids decrease cisplatin cytotoxicity and uptake in renal tubule epithelial cell lines. Cancer Chemother Pharmacol. 2000;45(1):43-49.
38.Yokoo K, Murakami R, Matsuzaki T, Yoshitome K, Hamada A, Saito H. Enhanced renal accumulation of cisplatin via renal organic cation transporter deteriorates acute kidney injury in hypomagnesemic rats. Clin Exp Nephrol.2009;13(6):578-584.
39.Burger H, Zoumaro-Djayoon A, Boersma AW, et al. Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2). Br J Pharmacol.2010;159(4):898-908.
40.Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther.2009;86(4):396-402.
41.Ciarimboli G, Deuster D, Knief A, et al. Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am J Pathol.2010;176(3):1169-1180.
42.Motohashi H, Sakurai Y, Saito H, et al. Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol.2002;13(4):866-874.
43.Kuo YM, Gybina AA, Pyatskowit JW, Gitschier J, Prohaska JR. Copper transport protein (Ctr1) levels in mice are tissue specific and dependent on copper status. J Nutr.2006;136(1):21-26.
44.Pabla N, Murphy RF, Liu K, Dong Z. The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Renal Physiol.2009;296(3):F505-511.
45.Ekborn A, Lindberg A, Laurell G, Wallin I, Eksborg S, Ehrsson H. Ototoxicity, nephrotoxicity and pharmacokinetics of cisplatin and its monohydrated complex in the guinea pig. Cancer Chemother Pharmacol.2003;51(1):36-42.
46.Zhang L, Hanigan MH. Role of cysteine S-conjugate beta-lyase in the metabolism of cisplatin. J Pharmacol Exp Ther.2003;306(3):988-994.
47.Wainford RD, Weaver RJ, Stewart KN, Brown P, Hawksworth GM. Cisplatin nephrotoxicity is mediated by gamma glutamyltranspeptidase, not via a C-S lyase governed biotransformation pathway. Toxicology.2008;249(2-3):184-193.
48.Liedert B, Pluim D, Schellens J, Thomale J. Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei. Nucleic Acids Res. 2006;34(6):e47.
49.Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene.2003;22(47):7265-7279.
50.Saad AA, Youssef MI, El-Shennawy LK. Cisplatin induced damage in kidney genomic DNA and nephrotoxicity in male rats: the protective effect of grape seed proanthocyanidin extract. Food Chem Toxicol.2009;47(7):1499-1506.
51.Bae EH, Lee J, Ma SK, et al. alpha-Lipoic acid prevents cisplatin-induced acute kidney injury in rats. Nephrol Dial Transplant.2009;24(9):2692-2700.
52.Yoshiki N, Kubota T, Aso T. Expression and localization of inducible nitric oxide synthase in human non-pregnant and early pregnant endometrium. Mol Hum Reprod.2000;6(3):283-287.
53.Lajer H, Kristensen M, Hansen HH, Christensen S, Jonassen T, Daugaard G. Magnesium and potassium homeostasis during cisplatin treatment. Cancer Chemother Pharmacol.2005;55(3):231-236.
54.Schnermann J, Levine DZ. Paracrine factors in tubuloglomerular feedback: adenosine, ATP, and nitric oxide. Annu Rev Physiol. 2003;65:501-529.
55.Santos NA, Bezerra CS, Martins NM, Curti C, Bianchi ML, Santos AC. Hydroxyl radical scavenger ameliorates cisplatin-induced nephrotoxicity by preventing oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Cancer Chemother Pharmacol.2008;61(1):145-155.
56.Chirino YI, Pedraza-Chaverri J. Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol.2009;61(3):223-242.
57.Aydinoz S, Uzun G, Cermik H, et al. Effects of different doses of hyperbaric oxygen on cisplatin-induced nephrotoxicity. Ren Fail. 2007;29(3):257-263.
58.Kuhad A, Pilkhwal S, Sharma S, Tirkey N, Chopra K. Effect of curcumin on inflammation and oxidative stress in cisplatin-induced experimental nephrotoxicity. J Agric Food Chem.2007;55(25):10150-10155.
59.Cetin R, Devrim E, Kilicoglu B, Avci A, Candir O, Durak I. Cisplatin impairs antioxidant system and causes oxidation in rat kidney tissues: possible protective roles of natural antioxidant foods. J Appl Toxicol 2006;26(1):42-46.
60.Jiang M, Wang CY, Huang S, Yang T, Dong Z. Cisplatin-induced apoptosis in p53-deficient renal cells via the intrinsic mitochondrial pathway. Am J Physiol Renal Physiol.2009;296(5):F983-993.
61.Ramesh G, Reeves WB. p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice. Am J Physiol Renal Physiol.2005;289(1):F166-174.
62.Choi DE, Jeong JY, Lim BJ, Lee KW, Shin YT, Na KR. Pretreatment with darbepoetin attenuates renal injury in a rat model of cisplatin-induced nephrotoxicity. Korean J Intern Med.2009;24(3):238-246.
63.Kang KP, Kim DH, Jung YJ, et al. Alpha-lipoic acid attenuates cisplatin-induced acute kidney injury in mice by suppressing renal inflammation. Nephrol Dial Transplant.2009;24(10):3012-3020.
64.Ramesh G, Reeves WB. Inflammatory cytokines in acute renal failure. Kidney Int Suppl.2004(91):S56-61.
65.Lee S, Kim W, Moon SO, et al. Rosiglitazone ameliorates cisplatin-induced renal injury in mice. Nephrol Dial Transplant.2006;21(8):2096-2105.
66.Sung MJ, Kim DH, Jung YJ, et al. Genistein protects the kidney from cisplatin-induced injury. Kidney Int.2008;74(12):1538-1547.
67.Aggarwal BB, Takada Y, Shishodia S, et al. Nuclear transcription factor NF-kappa B: role in biology and medicine. Indian J Exp Biol.2004;42(4):341-353.
68.Ramesh G, Kimball SR, Jefferson LS, Reeves WB. Endotoxin and cisplatin synergistically stimulate TNF-alpha production by renal epithelial cells. Am J Physiol Renal Physiol.2007;292(2):F812-819.
69.Mukhopadhyay P, Rajesh M, Pan H, et al. Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy. Free Radic Biol Med.2010;48(3):457-467.
70.Zhang B, Ramesh G, Norbury CC, Reeves WB. Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-alpha produced by renal parenchymal cells. Kidney Int.2007;72(1):37-44.
71.Lu LH, Oh DJ, Dursun B, et al. Increased macrophage infiltration and fractalkine expression in cisplatin-induced acute renal failure in mice. J Pharmacol Exp Ther.2008;324(1):111-117.
72.Eardley KS, Kubal C, Zehnder D, et al. The role of capillary density, macrophage infiltration and interstitial scarring in the pathogenesis of human chronic kidney disease. Kidney Int 2008;74(4):495-504.
73.Zhang B, Ramesh G, Uematsu S, Akira S, Reeves WB. TLR4 signaling mediates inflammation and tissue injury in nephrotoxicity. J Am Soc Nephrol.2008;19(5):923-932.
74.Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene.2007;26(22):3279-3290.
75.Owens DM, Keyse SM. Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene.2007;26(22):3203-3213.
76.Jo SK, Cho WY, Sung SA, Kim HK, Won NH. MEK inhibitor, U0126, attenuates cisplatin-induced renal injury by decreasing inflammation and apoptosis. Kidney Int.2005;67(2):458-466.
77.Kim YK, Kim HJ, Kwon CH, et al. Role of ERK activation in cisplatin-induced apoptosis in OK renal epithelial cells. J Appl Toxicol.2005;25(5):374-382.
78.Francescato HD, Costa RS, Junior FB, Coimbra TM. Effect of JNK inhibition on cisplatin-induced renal damage. Nephrol Dial Transplant.2007;22(8):2138-2148.
79.Brooks C, Wei Q, Cho SG, Dong Z. Regulation of mitochondrial dynamics in acute kidney injury in cell culture and rodent models. J Clin Invest 2009;119(5):1275-1285.
80.Lalier L, Cartron PF, Juin P, et al. Bax activation and mitochondrial insertion during apoptosis. Apoptosis.2007;12(5):887-896.
81.Jiang M, Wei Q, Pabla N, et al. Effects of hydroxyl radical scavenging on cisplatin-induced p53 activation, tubular cell apoptosis and nephrotoxicity. Biochem Pharmacol.2007;73(9):1499-1510.
82.Kaushal GP, Kaushal V, Hong X, Shah SV. Role and regulation of activation of caspases in cisplatin-induced injury to renal tubular epithelial cells. Kidney Int 2001;60(5):1726-1736.
83.Dutta J, Fan Y, Gupta N, Fan G, Gelinas C. Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene.30 2006;25(51):6800-6816.
84.Cummings BS, Schnellmann RG. Cisplatin-induced renal cell apoptosis: caspase 3-dependent and -independent pathways. J Pharmacol Exp Ther.2002;302(1):8-17.
85.Guo Y, Liu Y, Xu LG, Guo MY. [Protective effect of amifostine on cisplatin-induced nephrotoxicity and its mechanism]. Zhonghua Zhong Liu Za Zhi 2006;28(1):8-12.
86.Tsuruya K, Tokumoto M, Ninomiya T, et al. Antioxidant ameliorates cisplatin-induced renal tubular cell death through inhibition of death receptor-mediated pathways. Am J Physiol Renal Physiol.2003;285(2):F208-218.
87.Yonezawa A, Masuda S, Nishihara K, Yano I, Katsura T, Inui K. Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. Biochem Pharmacol 2005;70(12):1823-1831.
88.Ciarimboli G, Ludwig T, Lang D, et al. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol.2005;167(6):1477-1484.
89.Tzvetkov MV, Behrens G, O''Brien VP, Hohloch K, Brockmoller J, Benohr P. Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms. Pharmacogenomics 2011;12(10):1417-1427.
90.Iwata K, Aizawa K, Kamitsu S, et al. Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events. Clin Exp Nephrol.2012.
91.Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, Moriyama Y. A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci U S A.2005;102(50):17923-17928.
92.Masuda S, Terada T, Yonezawa A, et al. Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol.2006;17(8):2127-2135.
93.Tsuda M, Terada T, Asaka J, Ueba M, Katsura T, Inui K. Oppositely directed H+ gradient functions as a driving force of rat H+/organic cation antiporter MATE1. Am J Physiol Renal Physiol.2007;292(2):F593-598.
94.Tsuda M, Terada T, Mizuno T, Katsura T, Shimakura J, Inui K. Targeted disruption of the multidrug and toxin extrusion 1 (mate1) gene in mice reduces renal secretion of metformin. Mol Pharmacol.2009;75(6):1280-1286.
95.Watanabe S, Tsuda M, Terada T, Katsura T, Inui K. Reduced renal clearance of a zwitterionic substrate cephalexin in MATE1-deficient mice. J Pharmacol Exp Ther.2010;334(2):651-656.
96.Sato T, Masuda S, Yonezawa A, Tanihara Y, Katsura T, Inui K. Transcellular transport of organic cations in double-transfected MDCK cells expressing human organic cation transporters hOCT1/hMATE1 and hOCT2/hMATE1. Biochem Pharmacol.2008;76(7):894-903.
97.Yonezawa A, Masuda S, Yokoo S, Katsura T, Inui K. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther.2006;319(2):879-886.
98.Nakamura T, Yonezawa A, Hashimoto S, Katsura T, Inui K. Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. Biochem Pharmacol. 2010;80(11):1762-1767.
99.Tzvetkov MV, Vormfelde SV, Balen D, et al. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther.2009;86(3):299-306.
100.Ha Choi J, Wah Yee S, Kim MJ, et al. Identification and characterization of novel polymorphisms in the basal promoter of the human transporter, MATE1. Pharmacogenet Genomics.2009;19(10):770-780.
101.Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther.2004;75(1):13-33.
102.Sohn JW, Lee SY, Lee SJ, et al. MDR1 polymorphisms predict the response to etoposide-cisplatin combination chemotherapy in small cell lung cancer. Jpn J Clin Oncol 2006;36(3):137-141.
103.Campling BG, Young LC, Baer KA, et al. Expression of the MRP and MDR1 multidrug resistance genes in small cell lung cancer. Clin Cancer Res1997;3(1):115-122.
104.Han JY, Lim HS, Yoo YK, et al. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer 2007;110(1):138-147.
105.Pan JH, Han JX, Wu JM, Sheng LJ, Huang HN, Yu QZ. MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with non-small cell lung cancer. Respiration. 2008;75(4):380-385.
106.Han JY, Lim HS, Park YH, Lee SY, Lee JS. Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer. Lung Cancer.2009;63(1):115-120.
107.Jemnitz K, Heredi-Szabo K, Janossy J, Ioja E, Vereczkey L, Krajcsi P. ABCC2/Abcc2: a multispecific transporter with dominant excretory functions. Drug Metab Rev.2010;42(3):402-436.
108.Nies AT, Keppler D. The apical conjugate efflux pump ABCC2 (MRP2). Pflugers Arch. 2007;453(5):643-659.
109.Burger H, Loos WJ, Eechoute K, Verweij J, Mathijssen RH, Wiemer EA. Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Resist Updat.2011;14(1):22-34.
110.Taniguchi K, Wada M, Kohno K, et al. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res1996;56(18):4124-4129.
111.Korita PV, Wakai T, Shirai Y, et al. Multidrug resistance-associated protein 2 determines the efficacy of cisplatin in patients with hepatocellular carcinoma. Oncol Rep. 2010;23(4):965-972.
112.Han B, Gao G, Wu W, et al. Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients. Lung Cancer. 2011;72(2):238-243.
113.Sun N, Sun X, Chen B, et al. MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2010;65(3):437-446.
114.Friedberg EC. How nucleotide excision repair protects against cancer. Nat Rev Cancer 2001;1(1):22-33.
115.de Boer J, Hoeijmakers JH. Nucleotide excision repair and human syndromes. Carcinogenesis. 2000;21(3):453-460.
116.Wu W, Zhang W, Qiao R, et al. Association of XPD polymorphisms with severe toxicity in non-small cell lung cancer patients in a Chinese population. Clin Cancer Res.2009;15(11):3889-3895.
117.Goekkurt E, Al-Batran SE, Hartmann JT, et al. Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie. J Clin Oncol.10 2009;27(17):2863-2873.
118.Leibeling D, Laspe P, Emmert S. Nucleotide excision repair and cancer. J Mol Histol.2006;37(5-7):225-238.
119.Qian B, Zhang H, Zhang L, Zhou X, Yu H, Chen K. Association of genetic polymorphisms in DNA repair pathway genes with non-small cell lung cancer risk. Lung Cancer.2011;73(2):138-146.
120.Cho S, Kim MJ, Choi YY, et al. Associations between polymorphisms in DNA repair genes and TP53 mutations in non-small cell lung cancer. Lung Cancer. 2011;73(1):25-31.
121.Wakasugi M, Sancar A. Order of assembly of human DNA repair excision nuclease. J Biol Chem. Jun 25 1999;274(26):18759-18768.
122.Cui Y, Morgenstern H, Greenland S, et al. Polymorphism of Xeroderma Pigmentosum group G and the risk of lung cancer and squamous cell carcinomas of the oropharynx, larynx and esophagus. Int J Cancer.1 2006;118(3):714-720.
123.Canbay E, Cakmakoglu B, Zeybek U, et al. Association of APE1 and hOGG1 polymorphisms with colorectal cancer risk in a Turkish population. Curr Med Res Opin.2011;27(7):1295-1302.
124.Rouissi K, Bahria IB, Bougatef K, et al. The effect of tobacco, XPC, ERCC2 and ERCC5 genetic variants in bladder cancer development. BMC Cancer. 2011;11:101.
125.Hussain SK, Mu LN, Cai L, et al. Genetic variation in immune regulation and DNA repair pathways and stomach cancer in China. Cancer Epidemiol Biomarkers Prev.2009;18(8):2304-2309.
126.蘇郁虹. 探討人類α-與β- 8-oxoguanine DNA glycosylase 1蛋白於粒線體DNA基因修復之功能.國立成功大學.指導教授:黃溫雅 98年.
127.Mambo E, Chatterjee A, de Souza-Pinto NC, et al. Oxidized guanine lesions and hOgg1 activity in lung cancer. Oncogene 2005;24(28):4496-4508.
128.Li H, Hao X, Zhang W, Wei Q, Chen K. The hOGG1 Ser326Cys polymorphism and lung cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2008;17(7):1739-1745.
129.Duan WX, Hua RX, Yi W, et al. The Association between OGG1 Ser326Cys Polymorphism and Lung Cancer Susceptibility: A Meta-Analysis of 27 Studies. PLoS 2012;7(4):e35970.
130.Zhang H, Xu Y, Zhang Z, Li L. The hOGG1 Ser326Cys polymorphism and prostate cancer risk: a meta-analysis of 2584 cases and 3234 controls. BMC Cancer. 2011;11:391.
131.Srivastava K, Srivastava A, Sharma KL, Mittal B. Candidate gene studies in gallbladder cancer: a systematic review and meta-analysis. Mutat Res.2011;728(1-2):67-79.
132.Zhang Y, He BS, Pan YQ, Xu YQ, Wang SK. Association of OGG1 Ser326Cys polymorphism with colorectal cancer risk: a meta-analysis. Int J Colorectal Dis 2011;26(12):1525-1530.
133.Tell G, Quadrifoglio F, Tiribelli C, Kelley MR. The many functions of APE1/Ref-1: not only a DNA repair enzyme. Antioxid Redox Signal.2009;11(3):601-620.
134.Xi T, Jones IM, Mohrenweiser HW. Many amino acid substitution variants identified in DNA repair genes during human population screenings are predicted to impact protein function. Genomics.2004;83(6):970-979.
135.Lu J, Zhang S, Chen D, et al. Functional characterization of a promoter polymorphism in APE1/Ref-1 that contributes to reduced lung cancer susceptibility. FASEB J.2009;23(10):3459-3469.
136.Lo YL, Jou YS, Hsiao CF, et al. A polymorphism in the APE1 gene promoter is associated with lung cancer risk. Cancer Epidemiol Biomarkers Prev.2009;18(1):223-229.
137.Zhou B, Shan H, Su Y, et al. The association of APE1 -656T > G and 1349 T > G polymorphisms and cancer risk: a meta-analysis based on 37 case-control studies. BMC Cancer. 2011;11:521.
138.Wang M, Qin C, Zhu J, et al. Genetic variants of XRCC1, APE1, and ADPRT genes and risk of bladder cancer. DNA Cell Biol.2010;29(6):303-311.
139.Zhou K, Hu D, Lu J, et al. A genetic variant in the APE1/Ref-1 gene promoter -141T/G may modulate risk of glioblastoma in a Chinese Han population. BMC Cancer. 2011;11:104.
140.Berndt SI, Huang WY, Fallin MD, et al. Genetic variation in base excision repair genes and the prevalence of advanced colorectal adenoma. Cancer Res.2007;67(3):1395-1404.
141.Figueroa JD, Malats N, Real FX, et al. Genetic variation in the base excision repair pathway and bladder cancer risk. Hum Genet.2007;121(2):233-242.
142.Hadi MZ, Coleman MA, Fidelis K, Mohrenweiser HW, Wilson DM, 3rd. Functional characterization of Ape1 variants identified in the human population. Nucleic Acids Res 2000;28(20):3871-3879.
143.Gu D, Wang M, Zhang Z, Chen J. The DNA repair gene APE1 T1349G polymorphism and cancer risk: a meta-analysis of 27 case-control studies. Mutagenesis.2009;24(6):507-512.
144.Altaha R, Liang X, Yu JJ, Reed E. Excision repair cross complementing-group 1: gene expression and platinum resistance. Int J Mol Med 2004;14(6):959-970.
145.Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355(10):983-991.
146.Khrunin AV, Moisseev A, Gorbunova V, Limborska S. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J.2010;10(1):54-61.
147.Dinkova-Kostova AT, Talalay P. NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector. Arch Biochem Biophys.2010;501(1):116-123.
148.Siegel D, McGuinness SM, Winski SL, Ross D. Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics.1999;9(1):113-121.
149.Kiyohara C, Yoshimasu K, Takayama K, Nakanishi Y. NQO1, MPO, and the risk of lung cancer: a HuGE review. Genet Med.2005;7(7):463-478.
150.Rothman N, Smith MT, Hayes RB, et al. Benzene poisoning, a risk factor for hematological malignancy, is associated with the NQO1 609C-->T mutation and rapid fractional excretion of chlorzoxazone. Cancer Res1997;57(14):2839-2842.
151.Di Pietro G, Magno LA, Rios-Santos F. Glutathione S-transferases: an overview in cancer research. Expert Opin Drug Metab Toxicol.2010;6(2):153-170.
152.Townsend DM, Tew KD, He L, King JB, Hanigan MH. Role of glutathione S-transferase Pi in cisplatin-induced nephrotoxicity. Biomed Pharmacother.2009;63(2):79-85.
153.Huang YS, Chern HD, Su WJ, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology.2002;35(4):883-889.
154.張淑惠. 建立預測抗結核藥物治療期間肝損傷之評分系統暨評估基因型危險因子之重要性. 台北醫學大學.指導教授:陳香吟. 97年.
155.Han SX, Wang L, Wu DQ. The association between UGT1A7 polymorphism and cancer risk: A meta-analysis. Cancer Epidemiol.2012.
156.黃薇伊. 尿苷雙磷酸葡萄醣醛酸基轉移酶1A7(UGT1A7)基因型與肺癌之關聯研究. 台北醫學大學. 指導教授:陳香吟. 98年.
157.Dumont P, Leu JI, Della Pietra AC, 3rd, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet.2003;33(3):357-365.
158.Hildebrandt MA, Gu J, Wu X. Pharmacogenomics of platinum-based chemotherapy in NSCLC. Expert Opin Drug Metab Toxicol.2009;5(7):745-755.
159.謝雨純. 於接受cisplatin或Carboplatin治療之肺癌病人運用基因及非基因因子進行腎毒性之多元分析. 台北醫學大學. 指導教授:陳香吟. 100年;.
160.Parkin DP, Vandenplas S, Botha FJ, et al. Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am J Respir Crit Care Med.1997;155(5):1717-1722.
161.Martinez-Garcia A, Sastre I, Tenorio R, Bullido MJ. SNP genotyping with FRET probes. Optimizing the resolution of heterozygotes. Mol Cell Probes.2004;18(4):211-214.
162.Sullivan LM, Massaro JM, D''Agostino RB, Sr. Presentation of multivariate data for clinical use: The Framingham Study risk score functions. Stat Med 2004;23(10):1631-1660.
163.Mehta RL, Chertow GM. Acute renal failure definitions and classification: time for change? J Am Soc Nephrol.2003;14(8):2178-2187.
164.Waikar SS, Liu KD, Chertow GM. Diagnosis, epidemiology and outcomes of acute kidney injury. Clin J Am Soc Nephrol.2008;3(3):844-861.
165.Cubillo A, Cornide M, Lopez JL, et al. Renal tolerance to cisplatin in patients 70 years and older. Am J Clin Oncol.2001;24(2):192-197.
166.Donadio C, Lucchesi A, Ardini M, Cosio S, Fanucchi A, Gadducci A. Dose individualization can minimize nephrotoxicity due to carboplatin therapy in patients with ovarian cancer. Ther Drug Monit. 2009;31(1):63-69.
167.Caglar K, Kinalp C, Arpaci F, et al. Cumulative prior dose of cisplatin as a cause of the nephrotoxicity of high-dose chemotherapy followed by autologous stem-cell transplantation. Nephrol Dial Transplant.2002;17(11):1931-1935.
168.Chen Y, Li S, Brown C, et al. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet Genomics.2009;19(7):497-504.
169.Yu JJ, Lee KB, Mu C, et al. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J Oncol.2000;16(3):555-560.
170.Kohno T, Shinmura K, Tosaka M, et al. Genetic polymorphisms and alternative splicing of the hOGG1 gene, that is involved in the repair of 8-hydroxyguanine in damaged DNA. Oncogene.1998;16(25):3219-3225.
171.Janssen K, Schlink K, Gotte W, Hippler B, Kaina B, Oesch F. DNA repair activity of 8-oxoguanine DNA glycosylase 1 (OGG1) in human lymphocytes is not dependent on genetic polymorphism Ser326/Cys326. Mutat Res.2001;486(3):207-216.
172.Ma L, Chu H, Wang M, et al. hOGG1 Ser326Cys polymorphism is associated with risk of bladder cancer in a Chinese population: A case-control study. Cancer Sci.29 2012.
173.Dursun B, He Z, Somerset H, Oh DJ, Faubel S, Edelstein CL. Caspases and calpain are independent mediators of cisplatin-induced endothelial cell necrosis. Am J Physiol Renal Physiol. 2006;291(3):F578-587.
174.Hill JW, Hu JJ, Evans MK. OGG1 is degraded by calpain following oxidative stress and cisplatin exposure. DNA Repair (Amst).2008;7(4):648-654.
175.Zappa F, Ward T, Pedrinis E, Butler J, McGown A. NAD(P)H: quinone oxidoreductase 1 expression in kidney podocytes. J Histochem Cytochem.2003;51(3):297-302.
176.Nebert DW, Roe AL, Vandale SE, Bingham E, Oakley GG. NAD(P)H:quinone oxidoreductase (NQO1) polymorphism, exposure to benzene, and predisposition to disease: a HuGE review. Genet Med. 2002;4(2):62-70.
177.Wu X, Lu C, Ye Y, et al. Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy. Pharmacogenet Genomics.2008;18(11):955-965.
178.Visscher H, Ross CJ, Rassekh SR, et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol.2012;30(13):1422-1428.
|